1-3 of 3
Jenny Thirlway
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B-Cell Non-Hodgkin Lymphomas (NHL)

Sarit Assouline, Katharine L. Lewis, Rosemary Anne Harrup, Robert J Lutz, Jenny Thirlway, Jutta Deckert, David M Browning, Debra L Wood, Paul I. Nadler, Seung Tae Lee
Journal: Blood
Blood (2023) 142 (Supplement 1): 3095.
https://doi.org/10.1182/blood-2023-173955
Published: 2023
Journal Articles

IKS03, a Novel CD19-Targeted Antibody Drug Conjugate, Induces Target Dependent In Vivo Cell Killing of B-Cell Lymphoma Xenografts By DNA Crosslinking

Jutta Deckert, Jenny Thirlway, Justyna Mysliwy, Adam Lodge, Robert J Lutz
Journal: Blood
Blood (2023) 142 (Supplement 1): 1438.
https://doi.org/10.1182/blood-2023-174064
Published: 2023
Journal Articles

IKS03, a Next Generation CD19-Targeted Antibody Drug Conjugate, Shows Potent Activity in Preclinical Models of Aggressive B-Cell Lymphomas

Jutta Deckert, Jenny Thirlway, Justyna Mysliwy, Adam Lodge, Yun-Hee Park, Hyun-Min Ryu, Na Ra Han, Ho Young Song, Chul-Woong Chung, Robert J Lutz
Journal: Blood
Blood (2022) 140 (Supplement 1): 3134–3135.
https://doi.org/10.1182/blood-2022-158983
Published: 2022